These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 9744794)
1. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. Mailliot C; Sergeant N; Bussière T; Caillet-Boudin ML; Delacourte A; Buée L FEBS Lett; 1998 Aug; 433(3):201-4. PubMed ID: 9744794 [TBL] [Abstract][Full Text] [Related]
2. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. Sergeant N; Wattez A; Delacourte A J Neurochem; 1999 Mar; 72(3):1243-9. PubMed ID: 10037497 [TBL] [Abstract][Full Text] [Related]
3. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. Sergeant N; David JP; Lefranc D; Vermersch P; Wattez A; Delacourte A FEBS Lett; 1997 Aug; 412(3):578-82. PubMed ID: 9276470 [TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Ferrer I; Barrachina M; Puig B Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379 [TBL] [Abstract][Full Text] [Related]
5. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Adamec E; Mohan P; Vonsattel JP; Nixon RA Acta Neuropathol; 2002 Jul; 104(1):92-104. PubMed ID: 12070670 [TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946 [TBL] [Abstract][Full Text] [Related]
7. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640 [TBL] [Abstract][Full Text] [Related]
8. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Buée L; Delacourte A Brain Pathol; 1999 Oct; 9(4):681-93. PubMed ID: 10517507 [TBL] [Abstract][Full Text] [Related]
9. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450 [TBL] [Abstract][Full Text] [Related]
11. Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias. Delacourte A Dement Geriatr Cogn Disord; 1999; 10 Suppl 1():75-9. PubMed ID: 10436346 [TBL] [Abstract][Full Text] [Related]
12. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231 [TBL] [Abstract][Full Text] [Related]
13. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Scaravilli T; Tolosa E; Ferrer I Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076 [TBL] [Abstract][Full Text] [Related]
14. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. Ishizawa K; Ksiezak-Reding H; Davies P; Delacourte A; Tiseo P; Yen SH; Dickson DW Acta Neuropathol; 2000 Sep; 100(3):235-44. PubMed ID: 10965792 [TBL] [Abstract][Full Text] [Related]
15. Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities. Mailliot C; Bussière T; Hamdane M; Sergeant N; Caillet ML; Delacourte A; Buée L Ann N Y Acad Sci; 2000; 920():107-14. PubMed ID: 11193138 [TBL] [Abstract][Full Text] [Related]
16. Tau protein pathology in neurodegenerative diseases. Spillantini MG; Goedert M Trends Neurosci; 1998 Oct; 21(10):428-33. PubMed ID: 9786340 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. Chalmers KA; Love S J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683 [TBL] [Abstract][Full Text] [Related]
19. REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Tolnay M; Probst A Neuropathol Appl Neurobiol; 1999 Jun; 25(3):171-87. PubMed ID: 10417659 [TBL] [Abstract][Full Text] [Related]
20. Tangle evolution linked to differential 3- and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies. Uchihara T; Hara M; Nakamura A; Hirokawa K Histochem Cell Biol; 2012 Feb; 137(2):261-7. PubMed ID: 22116524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]